Fragment Screening and Vaccine - Drug Discovery Digest

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Fragment Screening

Vaccine

Tom Lehrer's guide to design of SARS-CoV-3 main protease inhibitors for treatment of COVID-32

Molecular Design

JANUARY 12, 2021

I consider it unlikely that a SARS-CoV-2 main protease inhibitor, designed from scratch, will be available in time to have real impact on the current pandemic (in saying this, I’m making the huge assumption that defeat does not get snatched from the jaws of victory on the vaccination front).

Fragment Screening

Fragment Screening Treatment Nurses Doctors

SARS-CoV-2 Protease Inhibitors: An Attractive Approach for Treating COVID-19

PerkinElmer

JUNE 3, 2022

1 Although effective COVID-19 vaccines have been developed, variants of SARS-CoV-2 have already emerged for which vaccines are less effective, and many people remain unvaccinated due to certain medical conditions, personal choice, or global access challenges.

Fragment Screening

Fragment Screening Clinical Trials Vaccine Pharmacokinetics

Webinars

Bridging Innovation & Patient Care: The Growing Role of AI

MORE WEBINARS

Tom Lehrer's guide to design of SARS-CoV-3 main protease inhibitors for treatment of COVID-32

SARS-CoV-2 Protease Inhibitors: An Attractive Approach for Treating COVID-19

Webinars

Stay Connected